Last reviewed · How we verify
carboplatin/paclitaxel (CP)
carboplatin/paclitaxel (CP) is a Small molecule drug developed by Sanofi. It is currently in Phase 3 development.
At a glance
| Generic name | carboplatin/paclitaxel (CP) |
|---|---|
| Sponsor | Sanofi |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer (PHASE2)
- Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma (PHASE2)
- Carboplatin-Paclitaxel Adjuvant Chemotherapy in the Treatment of Locally Advanced Cervical Cancer (PHASE2)
- Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL) (PHASE3)
- Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (PHASE2)
- Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer (PHASE2)
- Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) (PHASE3)
- Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- carboplatin/paclitaxel (CP) CI brief — competitive landscape report
- carboplatin/paclitaxel (CP) updates RSS · CI watch RSS
- Sanofi portfolio CI
Frequently asked questions about carboplatin/paclitaxel (CP)
What is carboplatin/paclitaxel (CP)?
carboplatin/paclitaxel (CP) is a Small molecule drug developed by Sanofi.
Who makes carboplatin/paclitaxel (CP)?
carboplatin/paclitaxel (CP) is developed by Sanofi (see full Sanofi pipeline at /company/sanofi).
What development phase is carboplatin/paclitaxel (CP) in?
carboplatin/paclitaxel (CP) is in Phase 3.
Related
- Manufacturer: Sanofi — full pipeline